Research analysts at BTIG Research started coverage on shares of DarioHealth (NASDAQ:DRIO – Get Free Report) in a report issued on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $6.00 price target on the stock. BTIG Research‘s target price suggests a potential upside of 76.47% from the company’s previous close.
DRIO has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of DarioHealth in a research report on Tuesday, October 6th. TD Cowen lowered their price objective on DarioHealth from $11.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, August 12th. Finally, Alliance Global Partners started coverage on DarioHealth in a research note on Wednesday, August 19th. They issued a “buy” rating and a $12.00 price target for the company. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $9.00.
Get Our Latest Stock Analysis on DRIO
DarioHealth Stock Down 9.8%
NASDAQ:DRIO opened at $3.40 on Tuesday. DarioHealth has a 12 month low of $3.01 and a 12 month high of $16.44. The firm has a fifty day simple moving average of $6.30 and a 200-day simple moving average of $7.97. The company has a current ratio of 2.31, a quick ratio of 1.92 and a debt-to-equity ratio of 0.56.
DarioHealth (NASDAQ:DRIO – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.37. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. The business had revenue of $5.18 million during the quarter, compared to analyst estimates of $5.92 million. As a group, research analysts expect that DarioHealth will post -2.94 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in DarioHealth stock. Nantahala Capital Management LLC acquired a new position in shares of DarioHealth Corp. (NASDAQ:DRIO – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 610,691 shares of the company’s stock, valued at approximately $4,030,561. Nantahala Capital Management LLC owned 8.32% of DarioHealth at the end of the most recent reporting period. Institutional investors and hedge funds own 33.39% of the company’s stock.
DarioHealth Company Profile
DarioHealth Corp. is a digital health company that develops technology-enabled solutions for managing chronic conditions. Its platform combines connected medical devices, mobile applications, data analytics and personalized coaching to help individuals monitor and improve their health.
The company’s offerings have focused on conditions including diabetes, hypertension, musculoskeletal disorders and behavioral health. Products and services may include connected blood glucose and blood pressure monitoring, digital programs for pain and mobility management, health coaching, educational content and tools that support healthier daily habits.
Featured Articles
- Five stocks we like better than DarioHealth
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.
